BTEK:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP)

ETF | Others |

Last Closing

USD 5.1775

Change

0.00 (0.00)%

Market Cap

N/A

Volume

4.15K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-08 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 204.07B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B

ETFs Containing BTEK:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.52% 50% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.52% 46% F 51% F
Trailing 12 Months  
Capital Gain 9.22% 50% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.22% 48% F 54% F
Trailing 5 Years  
Capital Gain -98.59% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.59% 1% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -14.85% 3% F 9% A-
Dividend Return -14.85% 3% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.09% 17% F 24% F
Risk Adjusted Return -38.99% 12% F 20% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.